{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:17:19Z","timestamp":1783786639416,"version":"3.55.0"},"reference-count":33,"publisher":"Japan Atherosclerosis Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5551\/jat.35121","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T22:04:32Z","timestamp":1466028272000},"page":"68-76","source":"Crossref","is-referenced-by-count":6,"title":["Anticoagulation Stability Depends on CHADS&lt;sub&gt;2&lt;\/sub&gt; Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation"],"prefix":"10.5551","volume":"24","author":[{"given":"Keita","family":"Odashiro","sequence":"first","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fukata","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Arita","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Faculty of Arts and Science, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD and Wallentin L; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151","DOI":"10.1056\/NEJMoa0905561"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA and Califf RM; ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891","DOI":"10.1056\/NEJMoa1009638"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J and Wallentin L; ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992","DOI":"10.1056\/NEJMoa1107039"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u2212pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M and Antman EM; ENGAGE AF-TIMI 48 Investigators: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104","DOI":"10.1056\/NEJMoa1310907"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Hylek EM: Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis 2013; 35: 333-335","DOI":"10.1007\/s11239-013-0900-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) JCS Joint Working Group: Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): digest version. Circ J 2014; 78: 1997-2021","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) JCS Joint Working Group: Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009): digest version. Circ J 2011; 75: 1258-1281","DOI":"10.1253\/circj.CJ-88-0010"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ohta Y, Tsuchihashi T, Onaka U and Hasegawa E: Clustering of cardiovascular risk factors and blood pressure control status in hypertensive patients. Intern Med 2010; 49: 1483-1487","DOI":"10.2169\/internalmedicine.49.3406"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW and Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870","DOI":"10.1001\/jama.285.22.2864"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Matsuyama K, Matsumoto M, Sugita T, Nishizawa J, Yoshida K, Tokuda Y and Matsuo T: Anticoagulant therapy in Japanese patients with mechanical mitral valve. Circ J 2002; 66: 668-670","DOI":"10.1253\/circj.66.668"},{"key":"11","unstructured":"11) Kitamura M, Koyanagi H, Kawada S, Hosoda Y, Kurosawa H, Takeuchi Y, Kawase M and Wanibuchi Y: Optimum anticoagulation control after bileaflet mechanical valve replacement: a prospective multi-institutional study (written in Japanese with English Abstract). Kyobu Geka 1999; 52: 1001-1004"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Rosendaal FR, Cannegieter SC, van der Meer FJ and Bri\u00ebt E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239","DOI":"10.1055\/s-0038-1651587"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Rose AJ, Reisman JI, Razouki Z and Ozonoff A: Percent time in range with warfarin as a performance measure: how long a sampling frame is needed? Jt Comm J Qual Patient Saf 2015; 41: 561-568","DOI":"10.1016\/S1553-7250(15)41073-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H and Hasegawa K, on behalf of the Fushimi AF Registry Investigators: Inappropriate use of oral anticoagulants for patients with atrial fibrillation: 1-year outcomes of the Fushimi AF Registry. Circ J 2014; 78: 2166-2172","DOI":"10.1253\/circj.CJ-14-0344"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Abdelhafiz AH, Myint MP, Tayek JA and Wheeldon NM: Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Ther 2009; 31: 1534-1539","DOI":"10.1016\/j.clinthera.2009.07.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ichihara N, Ishigami T and Umemura S: Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients. J Cardiol 2015; 65: 178-184","DOI":"10.1016\/j.jjcc.2014.08.008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Tincani E, Mazzali F and Morini L: Hypoalbuminemia as a risk factor for over-anticoagulation. Am J Med 2002; 112: 247-248","DOI":"10.1016\/S0002-9343(01)00957-3"},{"key":"18","unstructured":"18) Ali A, Bailey C and Abdelhafiz AH: Stroke prevention with oral anticoagulation in older people with atrial fibrillation: a pragmatic approach. Aging Dis 2012; 3: 339-351"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Plichart M, Berrut G, Maubourguet N, Jeandel C, Emeriau JP, Ankri J, Bouvier H, Ruault G and Hanon O: Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG). Drugs Aging 2013; 30: 1019-1028","DOI":"10.1007\/s40266-013-0127-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP and Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators: Patients&apos; time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBITAF registry. Am Heart J 2015; 170: 141-148","DOI":"10.1016\/j.ahj.2015.03.017"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) St\u00f6llberger C and Finsterer J: Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging 2013; 30: 949-958","DOI":"10.1007\/s40266-013-0119-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S and Aizawa Y: Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008; 117: 1255-1260","DOI":"10.1161\/CIRCULATIONAHA.107.744466"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bukowska A, Lendeckel U, Krohn A, Keilhoff G, ten Have S, Neumann KH and Goette A: Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney. Europace 2008; 10: 1212-1217","DOI":"10.1093\/europace\/eun206"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Zuo ML, Liu S, Chan KH, Lau KK, Chong BH, Lam KF, Chan YH, Lau YF, Lip GYH, Lau CP, Tse HF and Siu CW: The CHADS<sub>2<\/sub> and CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc scores predict new occurrence of atrial fibrillation and ischemic stroke. J Interv Card Electrophysiol 2013; 37: 47-54","DOI":"10.1007\/s10840-012-9776-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Chao TF, Cheng CC, Lin WS, Tsao HM, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Suenari K, Li CH, Liu SH, Hartono B, Wu TJ and Chen SA: Associations among the CHADS(2) score, atrial substrate properties, and outcome of catheter ablation in patients with paroxysmal atrial fibrillation. Heart Rhythm 2011; 8: 1155-1159","DOI":"10.1016\/j.hrthm.2011.03.016"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Fauchier L, Taillandier S and Clementy N: High risk in atrial fibrillation following an ablation procedure: the wide usefulness of the CHADS(2) score. Future Cardiol 2012; 8: 693-696","DOI":"10.2217\/fca.12.55"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hrynkiewicz-Szymanska A, Dluzniewski M, Platek AE, Szymanski FM, Syska-Suminska J, Klos-Szadryn A, Glinka M, Strojek M, Kuciej A and Tomaszewska-Kiecana M: Association of the CHADS<sub>2<\/sub> and CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. J Thromb Thrombolysis 2015; 40: 240-247","DOI":"10.1007\/s11239-014-1154-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Komatsu T, Sato Y, Ozawa M, Kunugita F, Ueda H, Tachibana H, Morino Y and Nakamura M: Relationship between CHADS<sub>2<\/sub> score and efficacy of antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation. Circ J 2013; 77: 639-645","DOI":"10.1253\/circj.CJ-12-0854"},{"key":"29","unstructured":"29) Melamed OC, Horowitz G, Elhayany A and Vinker S: Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011; 17: 232-237"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P and Schein JR: International normalized ratio stability in warfarin-experienced patients with non-valvular atrial fibrillation. Am J Cardiovasc Drugs 2015; 15: 205-211","DOI":"10.1007\/s40256-015-0120-9"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Maruyama T, Kishikawa T, Ito H, Kaji Y, Sasaki Y and Ishihara Y: Augmentation of pulmonary vein backflow velocity during left atrial contraction: a novel phenomenon responsible for progression of atrial fibrillation in hypertensive patients. Cardiology 2008; 109: 33-40","DOI":"10.1159\/000105324"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Tomita H, Kadokami T, Momii H, Kawamura N, Yoshida M, Inou T, Fukuizumi Y, Usui M, Funakoshi K, Yamada S, Aomori T, Yamamoto K, Uno T and Ando S, on behalf of ATTACK-WF research group: Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients. Thromb Res 2013; 132: 537-542","DOI":"10.1016\/j.thromres.2013.09.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J and Hylek EM: National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014; 129: 1407-1414","DOI":"10.1161\/CIRCULATIONAHA.113.002601"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/1\/24_35121\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T20:04:59Z","timestamp":1568059499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/1\/24_35121\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.35121","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}